See updated messages from the NIDA HRP scientific leadership team.
Funding Opportunities of Note
- NIDA Avant-Garde Award Program for HIV and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-23-269
- Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) PAR-23-125
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
Basic Research
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) RFA-DA-25-014
- NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-028
- NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-029
- Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) PAR-21-310
- Imaging - Science Track Award for Research Transition (I/START) (R03 Basic Experimental Studies with Humans Required) PAR-21-309
- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes. NOT-DA-20-018
- Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity. NOT-DA-21-014
- Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience. NOT-DA-20-022
- Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. NOT-DA-21-030
- Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional). RFA-DA-23-012
- Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-24-001
- Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed) RFA-DA-24-014
- Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed) RFA-DA-24-013
Clinical, Epidemiological, and Implementation Science Research
- Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) PA-21-205
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-023
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional) RFA-DA-23-024
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required). RFA-DA-23-008
- Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional). PAR-22-182
- Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional). PAR-22-183
- Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required) RFA-DA-23-006
- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required) RFA-DA-23-007
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) PAR-20-238
- Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches. NOT-DA-20-032
- Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) PAR-21-023
- Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed) PAR-20-236
- Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) PA-21-110
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) PA-21-180
- Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders. NOT-DA-21-019
- Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027
- Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) RFA-DA-24-037
- Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 Clinical Trials Not Allowed) RFA-DA-24-008
- Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 Clinical Trials Not Allowed) RFA-DA-24-009
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
- Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning. NOT-DA-21-007
Opportunities that Could be Basic or Clinical, Epidemiological, and Implementation Science Research
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Required) RFA-DA-25-020
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) RFA-DA-25-019
- Ending the HIV Epidemic: Focus on Justice Populations with SUD (R61/R33 Clinical Trial Required) RFA-DA-24-015
- Ending the HIV Epidemic: Resource Center to Engage Justice-Involved Populations (U24 Clinical Trial Optional) RFA-DA-24-022
- Ending the HIV Epidemic: Focus on Justice Populations with SUD-Data Coordination and Dissemination Center (UM1 Clinical Trial Optional) RFA-DA-24-023
- Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine – NOT-DA-24-001
- Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment, NOT-DA-24-002
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional). PAR-23-064
- Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders. NOT-DA-20-037
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-20-249
- Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders. NOT-DA-21-018
- Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19. NOT-DA-21-017